Compare KRYS & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | LEU |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.9B |
| IPO Year | 2017 | 1998 |
| Metric | KRYS | LEU |
|---|---|---|
| Price | $241.84 | $228.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $214.22 | ★ $235.80 |
| AVG Volume (30 Days) | 286.6K | ★ 926.0K |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 275.72 | 31.25 |
| EPS | ★ 6.66 | 6.17 |
| Revenue | $373,164,000.00 | ★ $454,100,000.00 |
| Revenue This Year | $36.14 | $1.93 |
| Revenue Next Year | $41.80 | $7.86 |
| P/E Ratio | ★ $36.72 | $40.36 |
| Revenue Growth | ★ 54.51 | 15.25 |
| 52 Week Low | $122.80 | $49.40 |
| 52 Week High | $248.60 | $464.25 |
| Indicator | KRYS | LEU |
|---|---|---|
| Relative Strength Index (RSI) | 74.92 | 35.36 |
| Support Level | $213.83 | $248.93 |
| Resistance Level | $248.60 | $274.00 |
| Average True Range (ATR) | 7.44 | 17.15 |
| MACD | 1.29 | -0.53 |
| Stochastic Oscillator | 78.92 | 12.14 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.